-
Engineering any genome, at any site, in any way
-
Focused on the advancement of new applications for CRISPR-based technologies
-
Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech
News
Caribou Biosciences Announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics
September 26, 2019BERKELEY, CA – September 26, 2019 – On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. (Intellia) and Caribou Biosciences, Inc. (Caribou). On October 17, 2018,...
Caribou Biosciences Announces Expansion of Scientific Advisory Board
February 12, 2019BERKELEY, CA – February 12, 2019 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of six new members: Emily Balskus, PhD;...
Our Approach
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.